SV2009003389A - Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer - Google Patents

Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer

Info

Publication number
SV2009003389A
SV2009003389A SV2009003389A SV2009003389A SV2009003389A SV 2009003389 A SV2009003389 A SV 2009003389A SV 2009003389 A SV2009003389 A SV 2009003389A SV 2009003389 A SV2009003389 A SV 2009003389A SV 2009003389 A SV2009003389 A SV 2009003389A
Authority
SV
El Salvador
Prior art keywords
compounds
pirimidina
pirido
ona
cancer treatment
Prior art date
Application number
SV2009003389A
Other languages
English (en)
Spanish (es)
Inventor
Chris Allen Buhr
Longcheng Wang
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of SV2009003389A publication Critical patent/SV2009003389A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SV2009003389A 2007-04-11 2009-10-09 Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer SV2009003389A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91116007P 2007-04-11 2007-04-11

Publications (1)

Publication Number Publication Date
SV2009003389A true SV2009003389A (es) 2010-04-27

Family

ID=39642739

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003389A SV2009003389A (es) 2007-04-11 2009-10-09 Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer

Country Status (25)

Country Link
US (2) US20100209340A1 (enExample)
EP (1) EP2142544B8 (enExample)
JP (1) JP2010523681A (enExample)
KR (1) KR20090130104A (enExample)
CN (1) CN101711249A (enExample)
AU (1) AU2008239596B2 (enExample)
BR (1) BRPI0810175A2 (enExample)
CA (1) CA2683820A1 (enExample)
CO (1) CO6241119A2 (enExample)
CR (1) CR11098A (enExample)
DO (1) DOP2009000242A (enExample)
EA (1) EA018964B1 (enExample)
EC (1) ECSP099722A (enExample)
ES (1) ES2425068T3 (enExample)
IL (1) IL201209A0 (enExample)
MA (1) MA31336B1 (enExample)
MX (1) MX2009010815A (enExample)
MY (1) MY150747A (enExample)
NI (1) NI200900183A (enExample)
NZ (1) NZ579945A (enExample)
SV (1) SV2009003389A (enExample)
TN (1) TN2009000389A1 (enExample)
UA (1) UA101315C2 (enExample)
WO (1) WO2008127712A1 (enExample)
ZA (1) ZA200906648B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767687B2 (en) * 2004-12-13 2010-08-03 Biogen Idec Ma Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
NZ594628A (en) * 2005-10-07 2013-04-26 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka
RS53627B1 (sr) * 2005-10-07 2015-04-30 Exelixis Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova upotreba kao inhibitora fosfatidilinozitol3-kinaze
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
WO2008032162A1 (en) * 2006-09-15 2008-03-20 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
RS52939B (sr) 2007-04-10 2014-02-28 Exelixis Inc. Postupci za lečenje kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
AU2008239655B2 (en) * 2007-04-11 2013-06-20 Exelixis, Inc. Pyrido (2, 3-d) pyrimidin-7-one compounds as inhibitors of PI3k-alpha for the treatment of cancer
WO2010039740A1 (en) * 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
RU2573569C2 (ru) * 2009-12-22 2016-01-20 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы фосфатидилинозитол-3-киназы на основе изоиндолинона
AR080151A1 (es) 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
JP5792819B2 (ja) 2010-09-14 2015-10-14 エクセリクシス， インク． Ｐｉ３ｋ−デルタの阻害剤ならびにそれらの使用法および製造法
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
EA201490905A1 (ru) 2011-11-01 2014-11-28 Экселиксис, Инк. N-(3-{[(3-{[2-хлор-5-(метокси)фенил]амино}хиноксалин-2-ил)амино]сульфонил}фенил)-2-метилаланинамид как ингибитор фосфатидилинозитол-3-киназы для лечения лимфопролиферативных злокачественных заболеваний

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2937284A (en) * 1958-05-01 1960-05-17 Burroughs Wellcome Co 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2005105801A1 (en) * 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
NZ594628A (en) * 2005-10-07 2013-04-26 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka
CN102746298A (zh) * 2005-10-07 2012-10-24 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
WO2008021389A2 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
WO2008032162A1 (en) * 2006-09-15 2008-03-20 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Also Published As

Publication number Publication date
CN101711249A (zh) 2010-05-19
ECSP099722A (es) 2009-12-28
CO6241119A2 (es) 2011-01-20
US20100209340A1 (en) 2010-08-19
CR11098A (es) 2010-01-27
MY150747A (en) 2014-02-28
DOP2009000242A (es) 2010-04-30
ES2425068T3 (es) 2013-10-11
EP2142544B8 (en) 2013-07-03
MA31336B1 (fr) 2010-04-01
IL201209A0 (en) 2010-05-31
BRPI0810175A2 (pt) 2014-12-30
EP2142544B1 (en) 2013-05-22
CA2683820A1 (en) 2008-10-23
US20130343988A1 (en) 2013-12-26
ZA200906648B (en) 2010-04-28
EA018964B1 (ru) 2013-12-30
JP2010523681A (ja) 2010-07-15
MX2009010815A (es) 2009-10-29
WO2008127712A1 (en) 2008-10-23
AU2008239596B2 (en) 2013-08-15
HK1139941A1 (en) 2010-09-30
NZ579945A (en) 2012-05-25
UA101315C2 (ru) 2013-03-25
EA200970936A1 (ru) 2010-02-26
EP2142544A1 (en) 2010-01-13
KR20090130104A (ko) 2009-12-17
NI200900183A (es) 2010-10-05
TN2009000389A1 (en) 2010-12-31
AU2008239596A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
SV2010003472A (es) Compuestos de pirazol
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
SV2010003767A (es) Compuestos pirazolicos 436
CU20110145A7 (es) Derivados de sulfonamida
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
NI201000003A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
CR20120130A (es) Compuestos de benzoxepina inhibidores de la pi3k y métodos de uso
CU20110078A7 (es) Compuestos de carbazol
UY33075A (es) Derivados de ciclohexano y usos de los mismos
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
DOP2009000200A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pimiridina como inhibidores hsp-90 para tratar el cancer
AR078613A1 (es) Derivados de sulfoxidos benzooxazolicos y benzotriazolicos inhibidores de autotaxinas, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores.
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
CO6341625A2 (es) Derivados de indol como agentes anticáncer
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
GT200600117A (es) Nuevos compuestos farmaceuticos

Legal Events

Date Code Title Description
FD Lapse